PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35406461-6	2022	The CDK7 inhibitor YKL-5-124 showed a strong impact on 2102EP, 2102EP-R, NCCIT and NCCIT-R cell lines, leaving the MPAF control cell line mostly unaffected.	YKL-5-124	19-28	cyclin dependent kinase 7	Homo sapiens	4-8
30905681-5	2019	YKL-5-124 causes arrest at the G1/S transition and inhibition of E2F-driven gene expression; these effects are rescued by a CDK7 mutant unable to covalently engage YKL-5-124, demonstrating on-target specificity.	YKL-5-124	0-9	cyclin dependent kinase 7	Homo sapiens	124-128
35198433-3	2021	Here we determined the effects of YKL-5-124, a novel covalent inhibitor with greater selectivity for CDK7 in neuroblastoma cells.	YKL-5-124	34-43	cyclin dependent kinase 7	Homo sapiens	101-105
35198433-6	2021	Results: CDK7 inhibition with YKL-5-124 did not lead to significant cell death, but resulted in aberrant cell cycle progression especially in MYCN-amplified cells.	YKL-5-124	30-39	cyclin dependent kinase 7	Homo sapiens	9-13
35198433-6	2021	Results: CDK7 inhibition with YKL-5-124 did not lead to significant cell death, but resulted in aberrant cell cycle progression especially in MYCN-amplified cells.	YKL-5-124	30-39	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	142-146
35198433-8	2021	Combining YKL-5-124 with the BRD4 inhibitor JQ1 resulted in synergistic cytotoxicity.	YKL-5-124	10-19	bromodomain containing 4	Homo sapiens	29-33
35198433-11	2021	Conclusions: The combination of CDK7 and BRD4 inhibition provides a therapeutic option for neuroblastoma and suggests that the addition of YKL-5-124 could improve the therapeutic efficacy of JQ1 and delay resistance to BRD4 inhibition.	YKL-5-124	139-148	cyclin dependent kinase 7	Homo sapiens	32-36
35198433-11	2021	Conclusions: The combination of CDK7 and BRD4 inhibition provides a therapeutic option for neuroblastoma and suggests that the addition of YKL-5-124 could improve the therapeutic efficacy of JQ1 and delay resistance to BRD4 inhibition.	YKL-5-124	139-148	bromodomain containing 4	Homo sapiens	41-45
35198433-11	2021	Conclusions: The combination of CDK7 and BRD4 inhibition provides a therapeutic option for neuroblastoma and suggests that the addition of YKL-5-124 could improve the therapeutic efficacy of JQ1 and delay resistance to BRD4 inhibition.	YKL-5-124	139-148	bromodomain containing 4	Homo sapiens	219-223
31883968-3	2020	Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling.	YKL-5-124	34-43	cyclin-dependent kinase 7	Mus musculus	18-22
31883968-3	2020	Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling.	YKL-5-124	34-43	cyclin-dependent kinase 7	Mus musculus	66-70